# Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome

> **NCT06676033** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 5 (actual)

## Conditions studied

- Leukemia, Chronic Lymphocytic
- Richter Syndrome

## Interventions

- **DRUG:** epcoritamab

## Key facts

- **NCT ID:** NCT06676033
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-18
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06676033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06676033, "Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06676033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*